The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
Open accessAbstract
Background Thrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill patients with Covid-19. Methods In an open-label, adaptive, multiplatform, randomized clinical trial, critically ill patients with severe Covid-19 were randomly assigned to a pragmatically defined regimen of either therapeutic-dose anticoagulation with heparin or pharmacologic thromboprophylaxis in accordance with local usual care. The primary outcome was organ support–free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of −1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge. Download a PDF of the Research Summary . Results The trial was stopped when the prespecified criterion for futility was met for therapeutic-dose anticoagulation. Data on the primary outcome were available for 1098 patients (534 assigned to therapeutic-dose anticoagulation and 564 assigned to usual-care thromboprophylaxis). The median value for organ support–free days was 1 (interquartile range, −1 to 16) among the patients assigned to therapeutic-dose anticoagulation and was 4 (interquartile range, −1 to 16) among the patients assigned to usual-care thromboprophylaxis (adjusted proportional odds ratio, 0.83; 95% credible interval, 0.67 to 1.03; posterior probability of futility [defined as an odds ratio <1.2], 99.9%). The percentage of patients who survived to hospital discharge was similar in the two groups (62.7% and 64.5%, respectively; adjusted odds ratio, 0.84; 95% credible interval, 0.64 to 1.11). Major bleeding occurred in 3.8% of the patients assigned to therapeutic-dose anticoagulation and in 2.3% of those assigned to usual-care pharmacologic thromboprophylaxis. Conclusions In critically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin did not result in a greater probability of survival to hospital discharge or a greater number of days free of cardiovascular or respiratory organ support than did usual-care pharmacologic thromboprophylaxis. (REMAP-CAP, ACTIV-4a, and ATTACC ClinicalTrials.gov numbers, NCT02735707 , NCT04505774 , NCT04359277 , and NCT04372589 .)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis), Helms, J., Tacquard, C., Severac, F., Leonard-Lorant, I., Ohana, M., Delabranche, X., Merdji, H., Clere-Jehl, R., Schenck, M., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06062-x · Cited by 2,792
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study
Wichmann, D., Sperhake, J.-P., Lütgehetmann, M., Steurer, S., Edler, C., Heinemann, A., Heinrich, F., Mushumba, H., Kniep, I., Schröder, A. S., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-2003 · Cited by 2,274
Klok, F. A., Kruip, M. J. H. A., van der Meer, N. J. M., Arbous, M. S., Gommers, D., Kant, K. M., Kaptein, F. H. J., van Paassen, J., Stals, M. A. M., Huisman, M. V., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.04.041 · Cited by 1,601
Incidence of venous thromboembolism in hospitalized patients with COVID‐19
Middeldorp, S., Coppens, M., van Haaps, T. F., Foppen, M., Vlaar, A. P., Müller, M. C. A., Bouman, C. C. S., Beenen, L. F. M., Kootte, R. S., Heijmans, J., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14888 · Cited by 1,447
COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection
Al-Samkari, H., Karp Leaf, R. S., Dzik, W. H., Carlson, J. C. T., Fogerty, A. E., Waheed, A., Goodarzi, K., Bendapudi, P. K., Bornikova, L., Gupta, S., et al. (2020) · Blood · doi:10.1182/blood.2020006520 · Cited by 1,351
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
Salama, C., Han, J., Yau, L., Reiss, W. G., Kramer, B., Neidhart, J. D., Criner, G. J., Kaplan-Lewis, E., Baden, R., Pandit, L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030340 · Cited by 1,291
Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence
Poissy, J., Goutay, J., Caplan, M., Parmentier, E., Duburcq, T., Lassalle, F., Jeanpierre, E., Rauch, A., Labreuche, J., Susen, S., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.047430 · Cited by 1,071
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
The ATTACC, A.-4. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105911 · Cited by 1,046
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults
Libster, R., Pérez Marc, G., Wappner, D., Coviello, S., Bianchi, A., Braem, V., Esteban, I., Caballero, M. T., Wood, C., Berrueta, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2033700 · Cited by 873
Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System
Bilaloglu, S., Aphinyanaphongs, Y., Jones, S., Iturrate, E., Hochman, J., & Berger, J. S. (2020) · JAMA · doi:10.1001/jama.2020.13372 · Cited by 818
INSPIRATION Investigators, Mazloomzadeh, S., Khaleghparast, S., Ghadrdoost, B., Mousavizadeh, M., Baay, M. R., Noohi, F., Sharifnia, H., Ahmadi, A., Tavan, S., et al. (2021) · JAMA · doi:10.1001/jama.2021.4152 · Cited by 625
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Lawler, P. R., Goligher, E. C., Berger, J. S., Neal, M. D., McVerry, B. J., Nicolau, J. C., Gong, M. N., et al. (n.d.) · Bern Open Repository and Information System (University of Bern) · doi:10.17863/cam.76384 · Cited by 581
Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis
Nopp, S., Moik, F., Jilma, B., Pabinger, I., & Ay, C. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12439 · Cited by 489
Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19
Nadkarni, G. N., Lala, A., Bagiella, E., Chang, H. L., Moreno, P. R., Pujadas, E., Arvind, V., Bose, S., Charney, A. W., Chen, M. D., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.041 · Cited by 452
Angus, D. C., Berry, S., Lewis, R. J., Al-Beidh, F., Arabi, Y., van Bentum-Puijk, W., Bhimani, Z., Bonten, M., Broglio, K., Brunkhorst, F., et al. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202003-192sd · Cited by 446
C-reactive protein and clinical outcomes in patients with COVID-19
Smilowitz, N. R., Kunichoff, D., Garshick, M., Shah, B., Pillinger, M., Hochman, J. S., & Berger, J. S. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa1103 · Cited by 436
Heparin as a therapy for COVID-19: current evidence and future possibilities
Hippensteel, J. A., LaRiviere, W. B., Colbert, J. F., Langouët-Astrié, C. J., & Schmidt, E. P. (2020) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00199.2020 · Cited by 203
More than an anticoagulant: Do heparins have direct anti-inflammatory effects?
Poterucha, T. J., Libby, P., & Goldhaber, S. Z. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-08-0620 · Cited by 199
McGlothlin, A. E., & Viele, K. (2018) · JAMA · doi:10.1001/jama.2018.17977 · Cited by 132
Tritschler, T., Mathieu, M., Skeith, L., Rodger, M. A., Middeldorp, S., Brighton, T., Sandset, P. M., Kahn, S. R., Angus, D., Blondon, M., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15094 · Cited by 96
Ionescu, F., Jaiyesimi, I. A., Petrescu, I., Lawler, P. R., Castillo, E. M., Maldonado, Y. M., Imam, Z., Narasimhan, M., Abbas, A. E., Konde, A. S., et al. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13533 · Cited by 95
Houston, B. L., Lawler, P. R., Goligher, E. C., Farkouh, M. E., Bradbury, C. A., Carrier, M., Džavík, V., Fergusson, D. A., Fowler, R., Galanaud, J. ‐., et al. (2020) · Clinical Trials · doi:10.1177/1740774520943846 · Cited by 65
Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19
Godoy, L. C., Goligher, E. C., Lawler, P. R., Slutsky, A. S., & Zarychanski, R. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.201240 · Cited by 55
Wijaya, I., Andhika, R., & Huang, I. (2020) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029620960797 · Cited by 52
Cited by
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
The ATTACC, A.-4. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105911 · Cited by 1,046
Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus
Raman, B., Bluemke, D. A., Lüscher, T. F., & Neubauer, S. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac031 · Cited by 650
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Lawler, P. R., Goligher, E. C., Berger, J. S., Neal, M. D., McVerry, B. J., Nicolau, J. C., Gong, M. N., et al. (n.d.) · Bern Open Repository and Information System (University of Bern) · doi:10.17863/cam.76384 · Cited by 581
Spyropoulos, A. C., Goldin, M., Giannis, D., Diab, W., Wang, J., Khanijo, S., Mignatti, A., Gianos, E., Cohen, M., Sharifova, G., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.6203 · Cited by 461
Ehrmann, S., Li, J., Ibarra-Estrada, M., Perez, Y., Pavlov, I., McNicholas, B., Roca, O., Mirza, S., Vines, D., Garcia-Salcido, R., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00356-8 · Cited by 402
Metadata
- Authors
- The REMAP-CAP, A.-4.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-26
- Volume
- 385
- Issue
- 9
- Pages
- 777-789
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4231969161
- Cited by
- 941
- References
- 28
- FWCI
- 62.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.